rhenium-186 hedp has been researched along with rhenium in 38 studies
| Studies (rhenium-186 hedp) | Trials (rhenium-186 hedp) | Recent Studies (post-2010) (rhenium-186 hedp) | Studies (rhenium) | Trials (rhenium) | Recent Studies (post-2010) (rhenium) |
|---|---|---|---|---|---|
| 75 | 32 | 19 | 2,106 | 111 | 774 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (28.95) | 18.2507 |
| 2000's | 26 (68.42) | 29.6817 |
| 2010's | 1 (2.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P | 1 |
| Botha, JM; Doman, MJ; Goedhals, L; Lötter, MG; Marais, J; Naudé, H; Otto, AC; Roodt, A; van Aswegen, A | 1 |
| Biersack, HJ; Dierke-Dzierzon, C; Müller, SC; Palmedo, H; Schoeneich, G | 1 |
| Holle, LH; Humke, U; Kirsch, CM; Oberhausen, E; Trampert, L; Ziegler, M | 1 |
| Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA | 1 |
| de Rooij, L; Geldof, AA; Newling, DW; Teule, GJ; Versteegh, RT | 1 |
| Kothari, K; Noronha, OP; Pillai, MR; Samuel, AM; Shimpi, HH; Unni, PR | 1 |
| Curley, T; Daghighian, F; Goldsmith, SJ; Graham, MC; Larson, SM; Liu, GB; Scher, HI; Yeh, SD | 1 |
| de Klerk, JM; Huiskes, AW; van Dijk, A; van Het Schip, AD; van Rijk, PP; Zonnenberg, BA | 1 |
| Hsieh, BT; Hsieh, JF; Lin, WY; Ting, G; Tsai, SC; Wang, SJ | 1 |
| Bohuslavizki, KH; Klutmann, S | 1 |
| Franke, WG; Grüning, T; Hliscs, R; Knapp, FF; Koch, R; Kropp, J; Liepe, K; Runge, R | 1 |
| Aras, G; Baltaci, S; Bedük, Y; Canakci, N; Ibiş, E; Küçük, NO; Ozalp, G; Soylu, A | 1 |
| Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P | 1 |
| Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R | 1 |
| Franke, WG; Hliscs, R; Kropp, J; Liepe, K | 1 |
| Brenner, W; Henze, E; Kampen, AM; Kampen, WU | 1 |
| Bergomi, S; Festa, A; Maini, CL; Pasqualoni, R; Rea, S; Sciuto, R; Semprebene, A | 1 |
| Bestagno, M; Cittanti, C; Colamussi, P; Dafermou, A; Giganti, M; Piffanelli, A | 1 |
| Banerjee, S; Chaudhari, PR; Kothari, K; Pillai, MR; Samuel, G; Sarma, HD; Unni, PR; Unnikrishnan, TP | 1 |
| Bangard, M; Biersack, HJ; Menzel, C; Palmedo, H; Risse, J; Rockstroh, JK; Schliefer, K | 1 |
| Li, S; Liu, J; Tian, M; Wang, J; Zhang, H; Zheng, X | 1 |
| Al-Deen, A; Buffa, FM; Chittenden, S; Cook, G; Dearnaley, DP; Flux, G; Gadd, J; Guy, M; Horwich, A; Huddart, RA; McCready, VR; Norman, AR; O'Sullivan, JM; Pomeroy, K; Treleaven, J | 1 |
| Brenner, W; Brümmer, C; Czech, N; Henze, E; Kampen, WU; Muhle, C; von Forstner, C; Zuhayra, M | 1 |
| Silberstein, EB; Taylor, AT | 1 |
| Buffa, FM; Chittenden, SJ; Dearnaley, DP; Flux, GD; Guy, MJ; McCready, VR; O'Sullivan, JM | 1 |
| Franke, WG; Hliscs, R; Knapp, FF; Kropp, J; Liepe, K; Runge, R | 1 |
| Albers, P; Biersack, HJ; Ezziddin, S; Fimmers, R; Guhlke, S; Joe, A; Knapp, FF; Manka-Waluch, A; Palmedo, H; Reinhardt, M; Roedel, R; Schmidt-Wolf, IG | 1 |
| Kotzerke, J; Kropp, J; Liepe, K; Runge, R | 1 |
| Bandurski, T; Derejko, M; Romanowicz, G; Scheffler, J | 1 |
| Endo, K; Li, S; Liu, J; Tanada, S; Tian, M; Zhang, H | 1 |
| de Klerk, JM; Lam, MG; van Rijk, PP | 1 |
| Dohmen, BM; Einsele, H; Kanz, L; Wiesmann, A | 1 |
| Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP | 1 |
| Buffa, FM; Coffey, J; Cook, G; Dearnaley, DP; Flux, G; Horwich, A; Huddart, RA; Johnson, B; McCready, VR; Norman, AR; O'Sullivan, JM; Parker, CC; Treleaven, J | 1 |
| El-Mabhouh, AA; Mercer, JR | 1 |
| Koutsikos, J; Leondi, A | 1 |
| Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A | 1 |
2 review(s) available for rhenium-186 hedp and rhenium
| Article | Year |
|---|---|
Application of rhenium-188 HEDP in bone metastases therapy.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Leukopenia; Organometallic Compounds; Pain; Palliative Care; Practice Patterns, Physicians'; Radiopharmaceuticals; Rhenium; Thrombocytopenia; Treatment Outcome | 2003 |
186Re-HEDP for metastatic bone pain in breast cancer patients.
Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Humans; Maximum Tolerated Dose; Organometallic Compounds; Pain; Palliative Care; Radiation Injuries; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Rhenium; Treatment Outcome | 2004 |
16 trial(s) available for rhenium-186 hedp and rhenium
| Article | Year |
|---|---|
[Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Male; Neoplasm Metastasis; Organometallic Compounds; Organotechnetium Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radioisotopes; Rhenium; Time Factors; Tomography, Emission-Computed | 1996 |
Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pain Measurement; Palliative Care; Prostatic Neoplasms; Radioisotopes; Rhenium; Time Factors | 1997 |
186Re-etidronate in breast cancer patients with metastatic bone pain.
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Organometallic Compounds; Pain, Intractable; Palliative Care; Radioisotopes; Rhenium | 1999 |
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Topics: Androgens; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Kidney; Male; Metabolic Clearance Rate; Organometallic Compounds; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Whole-Body Counting | 1999 |
Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP?
Topics: Aged; Blood Platelets; Bone and Bones; Bone Marrow; Bone Marrow Neoplasms; Diphosphonates; Etidronic Acid; Humans; Male; Organometallic Compounds; Organotechnetium Compounds; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Thrombocytopenia | 1999 |
Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium; Time Factors | 2000 |
[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Leukocyte Count; Male; Middle Aged; Organometallic Compounds; Pain; Palliative Care; Platelet Count; Prostatic Neoplasms; Radioisotopes; Rhenium; Strontium Radioisotopes; Tomography, X-Ray Computed | 2000 |
Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Etidronic Acid; Female; Humans; Infusions, Intravenous; Karnofsky Performance Status; Middle Aged; Organometallic Compounds; Pain Measurement; Pain, Intractable; Palliative Care; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Strontium Radioisotopes; Treatment Outcome | 2001 |
Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study.
Topics: Arthritis, Rheumatoid; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; Pain; Pain Management; Prospective Studies; Radioisotopes; Rhenium; Treatment Failure | 2001 |
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
Topics: Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Etidronic Acid; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Organometallic Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Radiotherapy; Recombinant Proteins; Rhenium | 2002 |
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Topics: Body Burden; Bone Marrow; Bone Neoplasms; Computer Simulation; Etidronic Acid; Humans; Injections, Intravenous; Male; Models, Biological; Organometallic Compounds; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Relative Biological Effectiveness; Rhenium; Statistics as Topic; Treatment Outcome; Whole-Body Counting | 2003 |
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Topics: Aged; Aged, 80 and over; Body Burden; Bone Marrow; Bone Neoplasms; Etidronic Acid; Half-Life; Humans; Injections, Intravenous; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Organometallic Compounds; Prostatic Neoplasms; Radiation Dosage; Radiometry; Rhenium; Tissue Distribution; Urinary Bladder; Whole-Body Counting | 2003 |
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Topics: Aged; Bone Neoplasms; Disease Progression; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Male; Organometallic Compounds; Pain Measurement; Pain, Intractable; Palliative Care; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Rhenium; Treatment Outcome | 2003 |
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Topics: Aged; Aged, 80 and over; Blood Cell Count; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Pain; Pain Measurement; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Rhenium; Treatment Outcome | 2003 |
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Combined Modality Therapy; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Middle Aged; Organometallic Compounds; Pain; Pain Management; Pamidronate; Radioisotopes; Rhenium | 2005 |
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Peripheral Blood Stem Cell Transplantation; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium; Transplantation, Autologous | 2006 |
20 other study(ies) available for rhenium-186 hedp and rhenium
| Article | Year |
|---|---|
Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
Topics: Adult; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Kidney; Male; Metabolic Clearance Rate; Organometallic Compounds; Palliative Care; Papio; Prostatic Neoplasms; Radiopharmaceuticals; Rhenium; Tissue Distribution; Urinary Bladder | 1997 |
[Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Organotechnetium Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy; Rhenium | 1997 |
Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells.
Topics: Animals; Cisplatin; Combined Modality Therapy; Drug Screening Assays, Antitumor; Etidronic Acid; Male; Organometallic Compounds; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radioisotopes; Rats; Rhenium; Tumor Cells, Cultured | 1999 |
Preparation, stability studies and pharmacological behavior of [186Re]Re-HEDP.
Topics: Animals; Chromatography, Thin Layer; Drug Stability; Etidronic Acid; Hydrogen-Ion Concentration; Isotope Labeling; Male; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Rhenium; Tissue Distribution | 1999 |
Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Diphosphonates; Etidronic Acid; Injections, Intravenous; Isotope Labeling; Neoplasm Metastasis; Organometallic Compounds; Rabbits; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Soft Tissue Neoplasms; Tissue Distribution; Whole-Body Counting | 1999 |
[Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Palliative Care; Prostatic Neoplasms; Radioisotopes; Rhenium; Treatment Outcome | 1999 |
Rhenium-188-HEDP in the palliative treatment of bone metastases.
Topics: Aged; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; Palliative Care; Radioisotopes; Rhenium | 2000 |
Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Organometallic Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radiopharmaceuticals; Rectal Neoplasms; Rhenium | 2000 |
Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Technetium Tc 99m Medronate | 2000 |
Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Topics: Aged; Bone and Bones; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Organometallic Compounds; Organophosphorus Compounds; Pain Management; Palliative Care; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Samarium; Thigh; Urinary Bladder | 2001 |
A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Humans; Injections, Intravenous; Male; Middle Aged; Organometallic Compounds; Pain; Pain Measurement; Palliative Care; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Strontium; Strontium Radioisotopes | 2001 |
186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation.
Topics: Analgesics; Animals; Bone Neoplasms; Etidronic Acid; Heterocyclic Compounds, 1-Ring; Injections, Intravenous; Male; Organometallic Compounds; Organophosphonates; Pain; Rabbits; Rats; Rats, Sprague-Dawley; Rhenium; Tissue Distribution | 2001 |
Rhenium-188 HEDP to treat painful bone metastases.
Topics: Bone Neoplasms; Etidronic Acid; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Aged; Organometallic Compounds; Pain; Pain Management; Palliative Care; Platelet Count; Radionuclide Imaging; Radiopharmaceuticals; Rhenium | 2001 |
Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
Topics: Animals; Bone and Bones; Connective Tissue; Etidronic Acid; Female; Organometallic Compounds; Organophosphorus Compounds; Rabbits; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Technetium Tc 99m Medronate; Urinary Bladder; Whole-Body Counting | 2003 |
EANM procedure guidelines for treatment of refractory metastatic bone pain.
Topics: Bone Neoplasms; Etidronic Acid; Europe; Humans; Nuclear Medicine; Organometallic Compounds; Organophosphorus Compounds; Pain, Intractable; Palliative Care; Patient Selection; Radiopharmaceuticals; Radiotherapy; Rhenium; Societies, Medical; Treatment Outcome | 2003 |
Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
Topics: Adult; Aged; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Follow-Up Studies; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Organometallic Compounds; Pain; Palliative Care; Radionuclide Imaging; Rhenium | 2003 |
Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
Topics: Bone and Bones; Disease-Free Survival; Etidronic Acid; Humans; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Organometallic Compounds; Peripheral Blood Stem Cell Transplantation; Radioisotopes; Remission Induction; Rhenium; Salvage Therapy; Transplantation, Autologous | 2005 |
188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Cattle; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Durapatite; Etidronic Acid; Female; Gemcitabine; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Rhenium; Tissue Distribution | 2008 |
Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium | 2008 |
Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organometallic Compounds; Pain; Pain Measurement; Predictive Value of Tests; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium | 2011 |